A lyophilized powder for the preparation of a solution for intravenous or parenteral injection comprising: from 1% to 30% of hydrocortisone hemisuccinate; from 40% to 98% of a bulking agent chosen from mannitol, trehalose, lactose, sucrose, raffinose or sorbitol; from 1% to 30% of a buffering agent; and use thereof for the preparation of a solution for intravenous or parenteral injection useful for the prevention or the treatment of the bronchopulmonary dysplasia in premature infants.

The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.

The present invention provides for a suspension formulation comprising a protein particle suspended in a non-aqueous vehicle, wherein the particle comprises a protein and a stabilizing agent, and wherein the residual water content of the suspended protein particle is less than 1.0 wt % based on total weight of the particle.

Compositions and methods for mucosal delivery of agents are provided. The emulsion compositions are intended for administration to a mucosal surface, such as oral, gastrointestinal and nasal mucosa. The emulsion compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.

This disclosure provides compositions and methods for treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.

The present disclosure relates to a composition for improving sleep quality, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof. The composition for improving sleep quality may improve the sleep quality by increasing melatonin secretion. In addition, in another aspect, the present disclosure provides a composition for alleviating stress, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof.

The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

A nanometric pharmaceutical composition in the form of liposomes or a nanoemulsion containing interference RNA strands comprising one or more of the following specific siRNA sequences: SEQ ID NO: 1; SEQ ID NO: 2; or SEQ ID NO: 3.

The invention discloses compositions comprising bisdemethoxycurcumin and methods for managing polycystic ovary syndrome (PCOS) and its associated conditions which include hormonal imbalance, obesity, hypothyroidism, hyperandrogenism, oxidative stress, inflammation, gut dysbiosis, hypercholesterolemia, cardiovascular complications, hyperglycemia and insulin resistance. The invention also discloses the potential of a curcuminoid composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin for use in the therapeutic management of PCOS.

An additive for use alone as a tablet or capsule or with a base product to produce an enhanced product that provides health benefits to a person who consumes or uses the additive, including stimulating naturally occurring enzymes in the person's body. The additive has one or more hydrogenated substances, such as Erythitol, Xylitol, hydrogenated dihydromyricetin and/or Quercetin dihydrate, and the flavonoid Dihydromyricetin. The flavonoid may be extracted from a Vine Tea plant and/or a plant chosen from the genus Hovenia, such as the Japanese raisin tree. The additive may also have one or more of a solvent, such as a bicarbonate compound or an alcohol solvent, a pH balancing acid and/or a preservatives. The base product may be a liquid, solid, powder, chewable, pharmaceutical, cosmetic or a lotion or other applied product. The enhanced product are a base product that is enhanced by the additive.